Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials
XTalks
NOVEMBER 6, 2020
Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.
75 
Let's personalize your content